Design Therapeutics DSGN
$9.02 −$0.30 (-3.22%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.02 0.00%
Open$9.33
Prev close$9.32
Day range$8.96 – $9.57
Volume281.9K
Market cap$577.61M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$22.23M-15.1% YoY
Net profit-$20.29M-19.4% YoY
Diluted EPS-$0.32-6.7% YoY
Free cash flow-$15.39M-37.9% YoY
Operating cash flow-$15.38M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-36.9%
Return on assets-34.6%
Return on invested capital-40.5%
Current ratio16.78
Liabilities / assets6.7%
Cash & investments$208.61M
Total debt$1.86M
Net cash (debt)$206.75M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $22.23M | $22.18M | $19.71M | $79.47M | $18.17M |
| Selling and Admin Expenses | $5.30M | $5.79M | $5.33M | $20.34M | $4.74M |
| -General & Admin Expense | $5.30M | $5.79M | $5.33M | $20.34M | $4.74M |
| Research & Development | $16.93M | $16.39M | $14.38M | $59.13M | $13.43M |
| Operating Profit | -$22.23M | -$22.18M | -$19.71M | -$79.47M | -$18.17M |
| Net Non-Operating Interest Income (Expense) | $1.94M | $2.01M | $2.07M | $9.68M | $2.17M |
| Non-Operating Interest Income | $1.94M | $2.01M | $2.07M | $9.68M | $2.17M |
| Pretax Profit | -$20.29M | -$20.17M | -$17.64M | -$69.79M | -$16.00M |
| Net Profit | -$20.29M | -$20.17M | -$17.64M | -$69.79M | -$16.00M |
| Profit from Continuing Operations | -$20.29M | -$20.17M | -$17.64M | -$69.79M | -$16.00M |
| Net Income to Parent Company | -$20.29M | -$20.17M | -$17.64M | -$69.79M | -$16.00M |
| Net Income to Common Stockholders | -$20.29M | -$20.17M | -$17.64M | -$69.79M | -$16.00M |
| Basic EPS | -$0.32 | -$0.32 | -$0.29 | -$1.22 | -$0.27 |
| Diluted EPS | -$0.32 | -$0.32 | -$0.29 | -$1.22 | -$0.27 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $216.81M | $215.13M | $230.44M | $226.20M | $226.20M |
| Total Current Assets | $213.96M | $212.01M | $227.05M | $223.78M | $223.78M |
| Cash and Cash Equivalents & Short-Term Investments | $208.61M | $207.40M | $222.82M | $219.85M | $219.85M |
| -Cash and Cash Equivalents | $15.25M | $12.91M | $12.77M | $16.86M | $16.86M |
| -Short Term Investments | $193.36M | $194.49M | $210.05M | $202.99M | $202.99M |
| Receivables | $1.74M | $1.79M | $1.82M | $1.68M | $1.68M |
| -Accrued Interest Receivable | $1.74M | $1.79M | $1.82M | $1.68M | $1.68M |
| Prepaid Assets | $3.61M | $2.83M | $2.40M | $2.26M | $2.26M |
| Total Non-Current Assets | $2.85M | $3.12M | $3.39M | $2.42M | $2.42M |
| Net PPE | $2.85M | $3.12M | $3.39M | $2.42M | $2.42M |
| -Gross PPE | $5.55M | $5.69M | $5.81M | $4.68M | $4.68M |
| -Accumulated Depreciation | -$2.71M | -$2.57M | -$2.42M | -$2.26M | -$2.26M |
| Total Liabilities | $14.61M | $13.27M | $12.39M | $13.70M | $13.70M |
| Total Current Liabilities | $12.75M | $11.24M | $10.19M | $13.06M | $13.06M |
| Payables | $2.08M | $3.14M | $2.28M | $2.31M | $2.31M |
| -Accounts Payable | $2.08M | $3.14M | $2.28M | $2.31M | $2.31M |
| Current Accrued Expenses | $6.09M | $4.68M | $5.05M | $5.22M | $5.22M |
| Short-Term Debt and Capital Lease Obligation | $655,000.00 | $631,000.00 | $536,000.00 | $890,000.00 | $890,000.00 |
| -Current Capital Lease Obligation | $655,000.00 | $631,000.00 | $536,000.00 | $890,000.00 | $890,000.00 |
| Total Non-Current Liabilities | $1.86M | $2.03M | $2.20M | $645,000.00 | $645,000.00 |
| Long Term Debt and Capital Lease Obligation | $1.86M | $2.03M | $2.20M | $645,000.00 | $645,000.00 |
| -Long Term Capital Lease Obligation | $1.86M | $2.03M | $2.20M | $645,000.00 | $645,000.00 |
| Total Equity | $202.20M | $201.86M | $218.05M | $212.50M | $212.50M |
| Stockholders' Equity | $202.20M | $201.86M | $218.05M | $212.50M | $212.50M |
| Capital Stock | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 |
| -Common Stock | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 |
| Additional Paid-In Capital | $558.97M | $537.43M | $532.96M | $509.10M | $509.10M |
| Retained Earnings | -$355.10M | -$334.81M | -$314.64M | -$297.01M | -$297.01M |
| Gains/Losses Not Affecting Retained Earnings | -$1.68M | -$771,000.00 | -$268,000.00 | $403,000.00 | $403,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.38M | -$15.52M | -$16.43M | -$54.36M | -$11.97M |
| Net cash flow from continuing operations | -$15.38M | -$15.52M | -$16.43M | -$54.36M | -$11.97M |
| Net Income from Continuing Operations | -$20.29M | -$20.17M | -$17.64M | -$69.79M | -$16.00M |
| Depreciation & Depletion & Amortization | $136,000.00 | $151,000.00 | $157,000.00 | $622,000.00 | $156,000.00 |
| Other Non-Cash Items | $2,000.00 | $74,000.00 | $69,000.00 | $406,000.00 | -$8,000.00 |
| Change in Working Capital | $703,000.00 | $564,000.00 | -$2.80M | $3.11M | $960,000.00 |
| -Change in Prepaid Assets | -$738,000.00 | -$391,000.00 | -$287,000.00 | -$1.38M | -$880,000.00 |
| -Change in Payables and Accrued Expense | $1.44M | $955,000.00 | -$2.51M | $4.49M | $1.84M |
| Net cash flow from investing | $189,000.00 | $15.06M | -$7.59M | $22.91M | -$11.58M |
| Net Cash Flow from Continuing Investing Activities | $189,000.00 | $15.06M | -$7.59M | $22.91M | -$11.58M |
| Net PPE Purchase and Sale | -$15,000.00 | -$21,000.00 | $0.00 | -$193,000.00 | -$34,000.00 |
| Net Investment Purchase and Sale | $204,000.00 | $15.08M | -$7.59M | $23.11M | -$11.55M |
| Financing Cash Flow | $17.53M | $605,000.00 | $19.93M | $25.74M | $25.32M |
| Net Cash Flow from Continuing Financing Activities | $17.53M | $605,000.00 | $19.93M | $25.74M | $25.32M |
| Net Common Stock Issuance | $17.26M | $0.00 | $19.91M | $24.85M | $24.85M |
| Proceeds from Stock Option Exercised | $277,000.00 | $605,000.00 | $27,000.00 | $891,000.00 | $470,000.00 |
| Ending Cash Balance | $15.25M | $12.91M | $12.77M | $16.86M | $16.86M |
| Net Change in Cash | $2.35M | $137,000.00 | -$4.09M | -$5.71M | $1.77M |
| Beginning Cash Balance | $12.91M | $12.77M | $16.86M | $22.56M | $15.09M |
| Free Cash Flow | -$15.39M | -$15.55M | -$16.43M | -$54.55M | -$12.00M |
No comments yet — be the first to weigh in on DSGN.
Sign in to join the discussion.